|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
35,410,000 |
Market
Cap: |
691.56(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$13.21 - $21.74 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
128,310 |
194,896 |
224,296 |
274,612 |
Total Sell Value |
$2,726,499 |
$3,969,036 |
$4,531,208 |
$5,316,305 |
Total People Sold |
4 |
5 |
5 |
6 |
Total Sell Transactions |
8 |
12 |
14 |
16 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baker Brothers Life Sciences Lp |
Director |
|
2022-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
20,000 |
2,710,597 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-04-26 |
4 |
D |
$9.99 |
$2,817 |
D/D |
(282) |
6,357 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
991 |
6,639 |
|
- |
|
Patel Sanj K |
CHAIRMAN & CEO |
|
2022-03-21 |
4 |
D |
$10.98 |
$59,797 |
D/D |
(5,446) |
17,756 |
|
- |
|
Patel Sanj K |
CHAIRMAN & CEO |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,555 |
23,202 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-03-21 |
4 |
D |
$10.98 |
$12,298 |
D/D |
(1,120) |
6,041 |
|
- |
|
Megna Michael R |
CHIEF ACCOUNTING OFFICER |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,231 |
7,161 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-03-21 |
4 |
D |
$10.98 |
$11,496 |
D/D |
(1,047) |
5,648 |
|
- |
|
Ragosa Mark |
CHIEF FINANCIAL OFFICER |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,019 |
6,695 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2022-03-21 |
4 |
D |
$10.98 |
$13,615 |
D/D |
(1,240) |
7,372 |
|
- |
|
Moat Ross |
CHIEF COMMERCIAL OFFICER |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,270 |
8,612 |
|
- |
|
Tessari Eben |
CHIEF OPERATING OFFICER |
|
2022-03-21 |
4 |
D |
$10.98 |
$16,042 |
D/D |
(1,461) |
112,213 |
|
- |
|
Tessari Eben |
CHIEF OPERATING OFFICER |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,611 |
113,674 |
|
- |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-03-21 |
4 |
D |
$10.98 |
$18,512 |
D/D |
(1,686) |
35,117 |
|
- |
|
Paolini John F. |
CHIEF MEDICAL OFFICER |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,676 |
36,803 |
|
- |
|
Moat Ross |
Chief Commercial Officer |
|
2022-03-16 |
4 |
D |
$10.13 |
$5,511 |
D/D |
(544) |
6,342 |
|
- |
|
Moat Ross |
Chief Commercial Officer |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
995 |
6,886 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2022-03-16 |
4 |
D |
$10.13 |
$19,470 |
D/D |
(1,922) |
4,647 |
|
- |
|
Patel Sanj K |
Chairman & CEO |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,569 |
6,569 |
|
- |
|
Paolini John F. |
Chief Medical Officer |
|
2022-03-16 |
4 |
D |
$10.13 |
$6,058 |
D/D |
(598) |
31,127 |
|
- |
|
Paolini John F. |
Chief Medical Officer |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,725 |
31,725 |
|
- |
|
Tessari Eben |
Chief Operating Officer |
|
2022-03-16 |
4 |
D |
$10.13 |
$6,899 |
D/D |
(681) |
109,063 |
|
- |
|
Tessari Eben |
Chief Operating Officer |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,964 |
109,744 |
|
- |
|
Ragosa Mark |
Chief Financial Officer |
|
2022-03-16 |
4 |
D |
$10.13 |
$3,069 |
D/D |
(303) |
3,676 |
|
- |
|
Ragosa Mark |
Chief Financial Officer |
|
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
872 |
3,979 |
|
- |
|
241 Records found
|
|
Page 7 of 10 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|